Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 426-400-9 | CAS number: 170222-39-6
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Repeated dose toxicity: oral
Administrative data
- Endpoint:
- short-term repeated dose toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- From November 7 to December 20, 1996
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 1 997
- Report date:
- 1997
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.7 (Repeated Dose (28 Days) Toxicity (Oral))
- Version / remarks:
- 1992
- GLP compliance:
- yes
- Limit test:
- no
Test material
- Reference substance name:
- Red RA 10463
- IUPAC Name:
- Red RA 10463
Constituent 1
Test animals
- Species:
- rat
- Strain:
- Wistar
- Remarks:
- Crl:(WI) BR
- Sex:
- male/female
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- polyethylene glycol
- Remarks:
- PEG 400
- Analytical verification of doses or concentrations:
- yes
- Duration of treatment / exposure:
- 28 days of treatment
- Frequency of treatment:
- daily (7 days per week)
Doses / concentrationsopen allclose all
- Dose / conc.:
- 50 mg/kg bw/day (actual dose received)
- Remarks:
- 28-day treatment period only
- Dose / conc.:
- 200 mg/kg bw/day (actual dose received)
- Remarks:
- 28-day treatment period only
- Dose / conc.:
- 1 000 mg/kg bw/day (actual dose received)
- Remarks:
- 28-day treatment period only
- Dose / conc.:
- 1 000 mg/kg bw/day (actual dose received)
- Remarks:
- 28-day treatment period plus additional 14-day recovery period
- No. of animals per sex per dose:
- 5 males and 5 females per group (6 groups in total)
- Control animals:
- yes, concurrent vehicle
- Positive control:
- none
Examinations
- Observations and examinations performed and frequency:
- Mortality/viability (twice daily), clinical signs (at least daily), body weight (weekly), food consumption (weekly), water consumption (subjective appraisal only), ophthalmoscopic examinations (during week 4 (all) and week 6 (recovery groups only)), haematology, biochemistry.
- Sacrifice and pathology:
- All animals surviving to the end of the observation period were deeply anaesthetised using ether vapour and subsequently exsanguinated. All animals assigned to the study were necropsied and descriptions of all macroscopic abnonmalities recorded. Samples of tissues and organs were collected from all animals at necropsy and fixed in neutral phosphate buffered 4 % formaldehyde solution. All organ and tissue samples were processed, embedded and cut at a thickness of 2 to 4 µm and stained with haematoxylin and eosin.
Results and discussion
Results of examinations
- Clinical signs:
- effects observed, treatment-related
- Description (incidence and severity):
- No clinical signs related to toxicity were observed, however, brown/purple discolouration of the fur, tail and urine occurred. Infrequent alopecia, salivation, rales, scabs and eye injury did not demonstrate relationship to treatment.
- Mortality:
- no mortality observed
- Body weight and weight changes:
- no effects observed
- Food consumption and compound intake (if feeding study):
- no effects observed
- Ophthalmological findings:
- no effects observed
- Haematological findings:
- effects observed, non-treatment-related
- Description (incidence and severity):
- The following slight haematological findings were within range of historical values and no correlation to treatment, and for this reason are considered to have arisen by chance and do not represent biological significance: red blood cell count, haemaglobin concentration and haematocrit were slightly decreased, and red cell distribution width was slightly elevated among high-dose females.
- Clinical biochemistry findings:
- no effects observed
- Organ weight findings including organ / body weight ratios:
- effects observed, treatment-related
- Description (incidence and severity):
- Final liver:body weight ratios were slightly elevated among high-dose males and females, however this finding was statistically significant only among males, and this finding was not evident among the animals which completed a two-week recovery phase. Absolute liver weights were also slightly elevated in this group of males, however this finding was not statistically significant.
- Gross pathological findings:
- effects observed, treatment-related
- Description (incidence and severity):
- Purple staining of the skin/tail among animals treated with 1000 mg/kg bw/day after 4 weeks. Black lungs which adhered to the heart and thymus, plus watery fluid in the thoracic cavity, was observed in one high-dose male only.
- Histopathological findings: non-neoplastic:
- effects observed, non-treatment-related
- Description (incidence and severity):
- Pericarditis in the.heart and pleuritis and haemorrhage in the lungs of one high-dose male was consistent with gavage injury.
Effect levels
- Dose descriptor:
- NOAEL
- Effect level:
- 1 000 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- organ weights and organ / body weight ratios
Target system / organ toxicity
- Critical effects observed:
- no
Applicant's summary and conclusion
- Conclusions:
- As no indication was found of morphologic or functional alterations in the liver, NOAEL (sub-acute, oral, rat) = 1000 mg/kg bw/day
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
